8-K: Genprex Unveils Positive Preclinical Data for Diabetes Gene Therapy GPX-002 at ADA Scientific Sessions

Genprex, Inc. announced positive preclinical research results for its diabetes gene therapy drug candidate, GPX-002, demonstrating transdifferentiation of alpha cells to insulin-secreting beta-like cells and improved glucose control in animal models.

Summary

• Genprex, Inc. issued a press release on June 24, 2025, announcing positive preclinical research findings for its diabetes gene therapy drug candidate, GPX-002.
• The research was presented at the 2025 American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, Illinois.
• GPX-002 utilizes recombinant adeno-associated virus (rAAV) infusion into the pancreatic duct to deliver Pdx1 and MafA genes, aiming to convert alpha cells into beta-like cells.
• In mouse models, the gene therapy successfully converted alpha cells into beta-like cells that physiologically secrete insulin, reversing diabetes without the need for immunosuppression.
• In non-human primate (NHP) models of streptozotocin-induced diabetes, one-month post-infusion, NHPs showed improved glucose tolerance and reduced insulin requirements.
• The beta-like cells continued to provide improved control of glucose levels after three months in animal models.
• Researchers noted increased pancreatic B and T lymphocyte populations in NHPs using steroid-sparing regimens in subsequent months.
• Temporary immunosuppression (IS) using a combination of rituximab, rapamycin, and steroids for a 3-month course was largely effective at preventing anti-viral immunity in NHPs.
• However, discontinuation of IS at 3 months post-infusion led to an immune response, indicating that IS in NHPs may need to be continued for longer durations.
• Current preclinical studies are evaluating viral efficacy after six months of IS in NHP models.
• The research demonstrated significantly elevated colocalization of insulin and glucagon in treated islets, suggesting alpha cells transdifferentiate into beta-like cells that produce insulin while retaining the capacity to produce glucagon.
• The novel rAAV gene therapy successfully led to transdifferentiation of alpha cells to beta-like cells with restoration of glucose homeostasis in NHPs.

Sentiment

Score: 7

Explanation: The sentiment is positive due to promising preclinical results for a significant disease, demonstrating a novel mechanism of action and positive outcomes in animal models. However, the identified challenge with the need for prolonged immunosuppression in NHPs slightly tempers the overall score, as it represents a hurdle that requires further research and optimization.

Positives

• GPX-002 demonstrated the ability to convert alpha cells into insulin-secreting beta-like cells through transdifferentiation.
• The gene therapy reversed diabetes in mouse models without requiring immunosuppression.
• In non-human primate (NHP) models, GPX-002 led to improved glucose tolerance and reduced insulin requirements one month post-infusion.
• The beta-like cells continued to provide improved glucose control for at least three months in animal models.
• The research suggests the creation of a new population of beta-like cells that physiologically secrete insulin while retaining the capacity to produce glucagon.
• The novel rAAV gene therapy successfully restored glucose homeostasis in NHPs.

Negatives

• In non-human primate (NHP) models, temporary immunosuppression (IS) was necessary for several months to prevent anti-viral immunity.
• Discontinuation of immunosuppression at three months post-infusion in NHPs led to an immune response, indicating that IS may need to be continued for longer periods.

Risks

• Genprex's ability to advance the clinical development, manufacturing, and commercialization of its product candidates in accordance with projected timelines.
• The timing and success of Genprex's clinical trials and regulatory approvals, including beliefs about the anticipated effects of GPX-002 and its potential as a therapeutic approach.
• The effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes.
• The effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or efforts aimed at optimizing and re-focusing Genprex's diabetes, oncology, and/or other clinical development programs.
• Genprex's future growth and financial status, including its ability to maintain compliance with Nasdaq Capital Market listing requirements and to continue as a going concern.
• Genprex's ability to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all.
• Genprex's commercial and strategic partnerships, including those with third-party vendors, suppliers, and manufacturers, and their ability to successfully perform and scale up the manufacture of its product candidates.
• Genprex's intellectual property and licenses.

Future Outlook

Researchers are continuing preclinical studies of GPX-002 therapy in non-human primate (NHP) models of both Type 1 and Type 2 diabetes to generate additional data. Current studies are evaluating viral efficacy after six months of immunosuppression in NHPs.

Industry Context

The announcement highlights progress in gene therapy for diabetes, a field with significant unmet medical needs. The approach of transdifferentiating alpha cells into insulin-producing beta-like cells represents a novel and potentially transformative strategy for diabetes treatment, aiming to restore physiological insulin secretion. This could offer a significant advantage over traditional insulin replacement therapies by addressing the root cause of insulin deficiency.

Stakeholder Impact

• Shareholders: Positive potential for future value creation if the drug candidate progresses successfully through clinical trials.
• Patients (with diabetes): Potential for a transformative new treatment option that could offer a functional cure by restoring physiological insulin production.
• Researchers: Validation of a novel gene therapy approach for diabetes.

Next Steps

• Continuing preclinical studies of GPX-002 therapy in non-human primate (NHP) models of both Type 1 and Type 2 diabetes to generate additional data.
• Evaluating viral efficacy after six months of immunosuppression in NHPs.

Key Dates

Keywords

Genprex, GPX-002, diabetes, gene therapy, preclinical research, alpha cells, beta cells, transdifferentiation, insulin, glucagon, rAAV, immunosuppression, Type 1 diabetes, Type 2 diabetes, ADA Scientific Sessions